+44 7723 059341
For new and expanding CDMOs, credibility rests on development capability: platforms that work, laboratories that are fit for purpose and teams that know what good looks like. Z2 brings experience from global CDMO development – including cell line construction governance across sites at Lonza Biologics – to help establish and strengthen credible, scalable process-development capabilities.
Demand is shifting: under the US BIOSECURE Act, sponsors are seeking capacity in the US, Europe, South Korea and India.1,2
How Z2 helps
- CLD and upstream platforms built
- Laboratories, equipment, workflows and SOPs
- Qualification strategy and operational readiness
- GMO containment, risk assessments and COSHH/BioCOSHH compliance
- Technology-transfer readiness as a receiving site
- Mentoring and training for process development teams
Where rushed timelines break
Receiving-site equipment that differs from the sending site; capability stood up without a map.
Where Z2 helps
Platforms, labs and teams designed with the client's transfer, comparability and CMC needs in mind.
Sources
- BIOSECURE Act: Arnold & Porter, Dec 2025; FDA Law Blog, Jun 2026; Zenas BioPharma 10-K FY2025.
- Vision Life Sciences. CDMO market analysis 2026, Feb 2026.
